Journals / Güncel Retina Dergisi / 2017 / Cilt: 1 - Sayı: 2

Follow-up in Dry-Form (Non-Neovascular) Age Related Macular Degeneration and Change to Wet Type

Kuru Tip (Non-Neovasküler) Yaşa Bağlı Maküla Dejenerasyonunda Takip ve Yaş Tipe Dönüşüm

Pages
128–134
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

So it is recommended to take images at regular intervals.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In early and mid-term period of age-related macular degeneration (AMD), macular drusens and pigmentary changes are seen.
📊
Key Findings & Data:About 20% of legal blindness is due to GA.
💡
Conclusion & Impact:So it is recommended to take images at regular intervals.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

In early and mid-term period of age-related macular degeneration (AMD), macular drusens and pigmentary changes are seen. Neovascularization and/or atrophy are seen in late term. RPE and photoreceptor loss in the macular area causes retinal atrophy or geographic atrophy (GA). About 20% of legal blindness is due to GA. This condition develops slowly according to foveal avascular zone involvement over the years. Progression of AMD is variable according to genetic factors, age and clinical features of macular lesions. Large, central located and in large number of drusens are risks for progression of AMD in end stage period. In general, about 10% of dry-type AMD patients show progression to wet type (neovascular) AMD. In AMD, measuring of the atrophy with imaging methods, is used to better determine its properties and to monitoring the progression. So it is recommended to take images at regular intervals. It is necessary to educate AMD patients and their families about these disease, risk factors and prevention. It is suggested to make regular consultation according to phase symptoms of AMD patients (use Amsler grid test and monitor visual acuity). Antioxidant vitamin and mineral support usage also recommended

Özet

Yaşa bağlı maküla dejenerasyonu (YBMD)'nun erken ve orta döneminde, makülada druzen ve pigmenter değişiklikler görülür. Geç dönemde neovaskülarizasyon ve/veya atrofi görülür. Maküler bölgedeki RPE ve fotoreseptör kaybı retinal atrofiye veya coğrafik atrofi (CA)'ye neden olur. Yasal körlüklerin yaklaşık %20'si CA kaynaklıdır. Bu durum yıllar içinde yavaşça ve foveal avasküler zonun tutulumuna göre gelişir. YBMD progresyonu genetik faktörler, yaş ve maküler lezyonların klinik özelliklerine göre değişiklik gösterir. Druzenin büyük, santral yerleşimli ve sayısının fazla olması ileri dönem YBMD'ye progresyon için ciddi risk oluşturur. Ayrıca bir gözde ileri YBMD olması diğer gözde ileri dönem YBMD'ye progresyon için ciddi risk oluşturur. Genel olarak kuru tip YBMD hastalarının yaklaşık %10 u yaş tip YBMD'ye progresyon göstermektedir. YBMD'de görüntüleme yöntemleri atrofinin ölçülmesi, özelliklerinin daha iyi belirlenmesi ve progresyonun takibi için kullanılmakta olup, düzenli aralıklarla çekimlerin yapılması önerilmektedir. YBMD hastalarını ve ailelerini bu hastalık, risk faktörleri ve önleyici tedbirler hakkında eğitmek gerekir. YBMD'nin evresine ve semptomlarına göre düzenli aralıklarla muayene, görme takibi için Amsler grid testinin kullanılması ve uygun olan hastalara antioksidan vitamin ve mineral desteğinin verilmesi önerilir

🔖

Cite This Article

BATUR, M., TEKİN, S., SEVEN, E. (2017). Follow-up in Dry-Form (Non-Neovascular) Age Related Macular Degeneration and Change to Wet Type. Güncel Retina Dergisi, Cilt: 1 - Sayı: 2, 128–134. https://ajindex.com/articles/224246

References (13)

  1. Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Global health. 2014; 2(2):e106–e16
  2. Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. N Engl J Med. 2008; 358(24):2606–17
  3. De Jong PT. Age-related macular degeneration. N Engl J Med. 2006; 355(14):1474–85
  4. Ferris FL, Wilkinson CP, Bird A, Chakravarthy U, Chew E, Csaky K, et al. Clinical classification of age-related macular degeneration. Ophthalmology. 2013;120:844–51
  5. Bird AC. Therapeutic targets in age-related macular disease. J Clin Invest. 2010;120:3033–41
  6. Patel HR, Eichenbaum D. Geographic atrophy: clinical impact and emerging treatments. Ophthalmic Surg Lasers Imaging Retina. 2015; 46(1):8–13
  7. Sunness JS, Rubin GS, Applegate CA, Bressler NM, Marsh MJ, Hawkins BS et al. Visual function abnormalities and prognosis in eyes with age-related geographic atrophy of the macula and good visual acuity. Ophthalmogy 1997; 104:1677–91
  8. Sunness JS, Gonzalez-Baron J, Applegate CA, Bressler NM, Tian Y, Hawkins B et al. Enlargement of atrophy and visual acuity loss in the geographic atrophy form of agerelated macular degeneration. Ophthalmology. 1999;106:1768-1779
  9. Pumariega NM, Smith RT, Sohrab MA, Letien V, Souied EH. A prospective study of reticular macular disease. Ophthalmology 2011;118:1619-1625
  10. Lindblad AS, Lloyd PC, Clemons TE, Gensler GR, Ferris FL 3rd, Klein ML, et al. Change in area of geographic atrophy in the Age-Related Eye Disease Study: AREDS report number 26. Arch Ophthalmol. 2009;127(9):1168–74
  11. Olcay K, Çakır A, Sönmez M, Düzgün E, Yıldırım Y. Kuru Tip Yasa Baglı Maküla Dejenerasyonu Hastalarında Otofloresans Görüntüleme Yöntemleri ile Lezyon Progresyon Hızının Degerlendirilmesi. Turk J Ophthalmol 2015;45:235-8 12- Sardell RJ, Persad PJ, Pan SS, Whitehead P, Adams LD, Laux RA et al. Progression Rate From Intermediate to Advanced Age-Related Macular Degeneration Is Correlated With the Number of Risk Alleles at the CFH Locus. Invest Ophthalmol Vis Sci. 2016;57(14):6107-15
  12. Joachim ND, Mitchell P, Kifley A, Wang JJ. Incidence, Progression, and Associated Risk Factors of Medium Drusen in Age-Related Macular Degeneration Findings From the 15-Year Follow-up of an Australian Cohort. JAMA Ophthalmol. 2015;133(6):698-705
  13. Klein R, Klein BE, Tomany SC, Meuer SM, Huang GH. Ten year incidence and